FDA Center for Drug Evaluation and Research develops strategic science and research agenda

Report available for public review and comment

A U.S. Food and Drug Administration report from its Center for Drug Evaluation and Research (CDER), available today in the Federal Register, identifies the current regulatory science needs that will guide CDER's strategic planning of internal research initiatives and contributions to the development of agency regulatory science efforts. 

"Communicating our science and research needs represents an important step in stimulating research and fostering collaborations with our external partners," said CDER director Janet Woodcock, M.D. "We look forward to hearing from and working with our stakeholders."

The report, "Identifying CDER's Science and Research Needs Report," identifies the following categories of science and research needs:
Improve access to post-market data sources and explore feasibility of their use in different types of analyses
Improve risk assessment and management strategies to reinforce the safe use of drugs
Evaluate the effectiveness and impact of different types of regulatory communications to the public and other stakeholders
Evaluate the link among product quality attributes, manufacturing processes and product performance
Develop and improve predictive models of safety and efficacy in humans
Improve clinical trial design, analysis and conduct
Enhance individualization of patient treatment

This docket will be open for review and public comment for 60 days after publication in the Federal Register notice.

For more information:
Identifying CDER's Science and Research Needs Report

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

Suggested Articles

Merck's Keytruda has new long-term survival results that the drugmaker hopes will help bolster its position in first-line NSCLC.

Last year at ESMO, AZ and Merck showed Lynparza topped its rivals at fending off prostate cancer. Now, Lynparza has helped patients live longer, too.

Merck and Eisai are trying to take their Keytruda-Lenvima combo into additional cancers, and new data provide a glimpse of where it might go next.